These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 18474125)

  • 1. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
    Okada K; Ohashi Y; Matsuo F; Uno S; Soh M; Nishima S
    Epidemiol Infect; 2009 Jan; 137(1):124-30. PubMed ID: 18474125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
    Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES
    JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control selection and confounding factors: A lesson from a Japanese case-control study to examine acellular pertussis vaccine effectiveness.
    Ohfuji S; Okada K; Nakano T; Ito H; Hara M; Kuroki H; Hirota Y
    Vaccine; 2017 Aug; 35(36):4801-4805. PubMed ID: 28818472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
    Beloradsky BH
    Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
    Robbins JB; Schneerson R; Trollfors B; Sato H; Sato Y; Rappuoli R; Keith JM
    J Infect Dis; 2005 Jan; 191(1):81-8. PubMed ID: 15593007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan.
    Horiuchi Y; Takahashi M; Konda T; Ochiai M; Yamamoto A; Kataoka M; Toyoizumi H; Arakawa Y
    Jpn J Infect Dis; 2001 Oct; 54(5):167-80. PubMed ID: 11754154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between acellular pertussis vaccine and seizures in early childhood.
    Huang WT; Gargiullo PM; Broder KR; Weintraub ES; Iskander JK; Klein NP; Baggs JM;
    Pediatrics; 2010 Aug; 126(2):263-9. PubMed ID: 20643726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
    Sato H; Sato Y
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.
    Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW
    JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.
    Bronson-Lowe D; Anderson SM
    Arch Pediatr Adolesc Med; 2009 May; 163(5):417-21. PubMed ID: 19414686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning protection after fifth dose of acellular pertussis vaccine in children.
    Klein NP; Bartlett J; Rowhani-Rahbar A; Fireman B; Baxter R
    N Engl J Med; 2012 Sep; 367(11):1012-9. PubMed ID: 22970945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.